Chemotherapy for Brain Tumors

ONCOLOGY

Volumn 12, Issue 4, 1998, Pages 537-543

  Pech, Irene V ^a   Peterson, Kendra ^b,d   Gregory Cairncross, J ^c  

^a Department of Neurology ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; PROCARBAZINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; GERM CELL TUMOR; HUMAN; MEDULLOBLASTOMA; OLIGODENDROGLIOMA; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; GERMINOMA; GLIOBLASTOMA; HUMANS; LYMPHOMA; MEDULLOBLASTOMA; OLIGODENDROGLIOMA;

EID: 0031957476     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. DeAngelis LM, Yahalom J, Heinemann MH, et al: Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy. Neurology 40:80-86, 1990.
2. Freilich RJ, DeAngelis LM Primary central nervous system lymphoma. Neurol Clin 13:901-914, 1995.
3. Geppert M, Ostertag CB, Seitz G, et al: Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol 80:629-634, 1990.
4. Kawakami Y, Tabuchi K, Ohnisht R: Primary central nervous system lymphoma. J Neurosurg 62:522-527, 1985.
5. Loeffler JS, Ervin TJ, Matich P, et al: Primary lymphomas of the central nervous system: Patterns of failure and factors that influence survival. J Clin Oncol 3:490-494, 1985.
6. Pollack IF, Lunsford LD, Flickinger JC, et al: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939-947, 1989.
7. Gabbai AA, Hochberg FH, Linggood R: High dose methotrexate therapy of primary brain lymphoma. J Neurosurg 70:190-194, 1988.
8. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality treatment for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992.
9. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580-1590, 1991.
10. Stewart DJ, Russell N, Dennery M, et al: Cyclophosphamide, Adriamycin, vincristine and dexamethasone in the treatment of bulky CNS lymphomas. J Neurooncol 2:289, 1984.
11. Cher L, Glass J, Harsh GR, et al: Treatment of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results Neurology 46:1757-1759, 1996.
12. Chamberlain MC, Levin VA: Primary central nervous system lymphoma: A role for adjuvant chemotherapy. J Neurooncol 14:271-275, 1992
13. Lachance DH, Brizel DM, Gockerman JP, et al: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44:1721-1727, 1994.
14. Schultz C, Scott C, Sherman W, et al: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 14:556-564, 1996.
15. DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 9:63-71, 1995.
16. Forsyth, PA, Yahalom J, DeAngelis LM: Combined modality therapy in patients with primary central nervous system lymphoma in AIDS. Neurology 44:1473-1479, 1994
17. Freilich RJ, Delattre JY, Monjour A, et al: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435-439, 1996
18. Hubbard JL, Scheithauer BW, Kispert DB, et al: Adult cerebellar medulloblastoma. The pathological, radiographic and clinical spectrum. J Neurosurg 70:536-544, 1989.
19. Cohen ME, Duffner PK: Medulloblastomas, in Cohen ME, Duffner PK (eds): Brain Tumors in Children, 2nd ed, pp 177-201. New York, Raven Press, 1994.
20. Wisoff JH, Epstein FI: Management of pediatric brain tumors, in Morantz RA, Walsh JW (eds): Brain Tumors; A Comprehensive Text, pp 581-611. New York, Marcel Dekker, 1993.
21. Friedman HS, Oakes WJ, Bigner SH, et al: Medulloblastoma: Tumor biological and clinical perspectives. J Neurooncol 11:1-15, 1991.
22. Tait DM, Thorton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Pediatric Oncology (SIOP I). Eur J Cancer 26:464-469, 1990.
23. Evans AE, Jenkin DT, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone. J Neurosurg 72:572-582, 1990.
24. Bloom HJG, Bessell EM: Medulloblastoma in adults: A review of 47 patients between 1952 and 1981. Int J Radiat Oncol Biol Phys 18:763-772, 1990.
25. Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690-698, 1994.
26. Deutsch M, Thomas PR, Krischer J, et al: Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3600 cGy/20) with reduced neuraxis irradiation (2340 cGy/13) in patients with low-stage medulloblastoma: A combined Children's Cancer Group-Pediatric Oncology Group study. Pediatr Neurosurg 24:167-176, 1996.
27. Shaw EG, Scheithauer BW, O'Fallon JR, et al: Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 76:428-434, 1992
28. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988.
29. Levin VA, Edwards MS, Wright DC, et al: Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-241, 1980.
30. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma J Clin Oncol 12:2013-2021, 1994
31. Glass J, Hochberg FH, Gruber ML, et al: The treatment of oligodendrogliomas and mixed oligodendrogliomas-astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745, 1992.
32. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 31:78-82, 1992.
33. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27:573-574, 1990.
34. Brown M, Cairncross JG, Vick NA et al: Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology 40(suppl):397-398, 1990.
35. Poisson M, Pereon Y, Chiras J, et al: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10:139-144, 1991.
36. Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma. A case report. J Neurooncol 9:57-61, 1990.
37. Kyritsis AP, Yung WKA, Bruner J, et al: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32:365-371, 1993.
38. Allen JC Controversies in the management of intracranial germ cell tumors. Neurol Clin 9:441-452, 1991.
39. Kida Y, Kobayashi T, Yoshida J, et al: Chemotherapy with cisplatin for AFP-secreting germ-cell tumors of the central nervous system. J Neurosurg 65:470-475, 1986.
40. Allen JC, Bosl G, Walker R: Chemotherapy trials in recurrent primary intracranial germ cell tumors. J Neurooncol 3:147-152, 1985.
41. Patel SR, Buckner JC, Smithson WA, et al: Cisplatin-based chemotherapy in primary central nervous system germ cell tumors. J Neurooncol 12:47-52, 1992.
42. Castaneda VL, Parmley RT, Geiser CF, et al: Postoperative chemotherapy for primary intracranial germ cell tumor. Med Pediatr Oncol 18:299-303, 1990.
43. Allen JC, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55 749-756, 1981.
44. Kobayashi T, Yoshida J, Ishiyama J, et al: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors- An experimental and clinical study. J Neurosurg 70:676-681, 1992.
45. Packer RJ, Sutton LN, Rorke LB, et al: Intracranial embryonal cell carcinoma. Cancer 54:520-524, 1984.
46. Balmaceda C, Heller G, Rosenblum M, et al: Chemotherapy without irradiation - A novel approach for newly diagnosed CNS germ cell tumors: Results of an international cooperative trial J Clin Oncol 14:2908-2915, 1996.
47. Fine HA, Dear KBH, Loeffler JS, et al. Meta-analysis of radiation therapy with and without chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993.
48. Levin VA, Silver P, Hannigan J, et al: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990.
49. Friedman SH, Oakes WJ: The chemotherapy of posterior fossa tumors in childhood. J Neurooncol 5:217-229, 1991.
50. Inamura T, Nomura T, Bartus RT, et al: Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors J Neurosurg 81:752-758, 1994.
51. Kleinschmidt-DeMasters BK, Geier JM: Pathology of high-dose intra-arterial BCNU. Surg Neurol 31:435-443, 1989.
52. Shapiro WR, Green GB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76:772-781, 1992.
53. Brem H, Domb A, Lenartz D, et al: Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid and sebacic acid. J Control Rel 19:325-330, 1992.
54. Domb A, Bogdansky S, Olivi A , et al Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants Polymer Preprints 32:219-220, 1991.
55. Brem H, Piantadosi S, Burger PC, et al: Intraoperative controlled delivery of chemotherapy by biodegradable polymers. Safety and effectiveness for recurrent gliomas evaluated by a prospective, multi-institutional placebo-controlled clinical trial. Lancet 345:1008-1012, 1995
56. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors Eur J Cancer 29A:940-942, 1993.